Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S. Business Wire - Wed Jan 14, 7:49AM CST

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine...

RDY : 13.68 (-0.22%)
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies Business Wire - Tue Dec 2, 2025

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1 st two cohorts...

RDY : 13.68 (-0.22%)
Zoetis Inc logo on phone-by viewimage via Shutterstock
Is Zoetis Stock Underperforming the Dow? Barchart - Tue Nov 25, 2025

Zoetis's shares are trailing the broader Dow Jones index, yet analysts still project upside, signaling confidence in the company’s long-term recovery potential.

RDY : 13.68 (-0.22%)
ZTS : 124.05 (-0.28%)
$DOWI : 49,098.71 (-0.58%)
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025 Business Wire - Wed Oct 22, 2025

Aurigene Oncology Limited , a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein...

RDY : 13.68 (-0.22%)
Dr. Reddy’s Laboratories to Announce Q2FY26 Results on October 24, 2025 Tipranks - Wed Oct 15, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Dr Reddy’s...

RDY : 13.68 (-0.22%)
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire - Mon Aug 25, 2025

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS

RDY : 13.68 (-0.22%)
COYA : 4.72 (-0.21%)
Dr. Reddy’s Q1FY26 Financial Results Business Wire - Wed Jul 23, 2025

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned...

RDY : 13.68 (-0.22%)
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals Zacks Investment Research - Wed Apr 16, 2025

For Immediate ReleaseChicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2448907/3-generic-drug-stocks-to-watch-amid-trade-war-jitters-inflation-woesWhile...

SDZNY : 81.2300 (+3.14%)
RDY : 13.68 (-0.22%)
TEVA : 31.81 (+0.47%)
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes Zacks Investment Research - Tue Apr 15, 2025

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from...

SDZNY : 81.2300 (+3.14%)
RDY : 13.68 (-0.22%)
TEVA : 31.81 (+0.47%)
Author
2 overlooked stocks that crushed earnings but traded lower MarketBeat - Mon Nov 20, 2023

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

WHR : 85.43 (-4.72%)
BAC : 51.72 (-1.39%)
RDY : 13.68 (-0.22%)
NVS : 147.14 (+1.48%)
TEVA : 31.81 (+0.47%)
HSBC : 83.94 (+0.23%)
DB : 39.08 (-0.15%)
PFE : 25.65 (-0.08%)
BMY : 54.65 (-0.53%)

Barchart Exclusives

Applied Materials Hits New High: Is AMAT Stock Poised for Continued Gains in 2026? Barchart - 54 minutes ago
Applied Materials appears well positioned to benefit from the AI-driven investment cycle. However, the stock’s valuation is a concern. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot